Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 1;121(19):3403-11.
doi: 10.1002/cncr.29496. Epub 2015 Jul 6.

Applying precision medicine to the active surveillance of prostate cancer

Chad A Reichard  1 , Andrew J Stephenson  1 , Eric A Klein  1
Affiliations

Applying precision medicine to the active surveillance of prostate cancer

Chad A Reichard et al. Cancer. .

Abstract

The recent introduction of a variety of molecular tests will potentially reshape the care of patients with prostate cancer. These tests may make more accurate management decisions possible for those patients who have been "overdiagnosed" with biologically indolent disease, which represents an exceptionally small mortality risk. There is a wide range of possible applications of these tests to different clinical scenarios in patient populations managed with active surveillance. Cancer 2015;121:3435-43. © 2015 American Cancer Society.

Keywords: active surveillance; biomarker; gene expression; prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Incorporation of molecular risk profiling into active surveillance (AS) protocols. PSA indicates prostate‐specific antigen.
See this image and copyright information in PMC

References

    1. Klotz L, Vesprini D, Sethukavalan P, et al. Long‐term follow‐up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33:272‐277. - PubMed
    1. Bishoff JT, Freedland SJ, Gerber L, et al. Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy. J Urol. 2014;192:409‐414. - PubMed
    1. Shipitsin M, Small C, Choudhury S, et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy‐sampling error. Br J Cancer. 2014;111:1201‐1212. - PMC - PubMed
    1. Klein EA, Cooperberg MR, Magi‐Galluzzi C, et al. A 17‐gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014;66:550‐560. - PubMed
    1. American Cancer Society . Cancer Facts & Figures 2015. Available at: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2.... Accessed April 28, 2015.